Implantica AG is Lichtenstein-based medical technology Company, whose mission is to provide effective treatment for serious health conditions and to improve patients' life through the use of advanced technologies in the human body, ultimately aiming to reduce costs and increase efficiency in the healthcare System. The therapies developed by Implantica are based on implants that are inserted into the patient's body and remain in the body permanently or semi-permanently to replace bodily functions and/or treat diseases. The Company focuses on the discovery, development and prospective commercialization of medical products and implants that are intended for use in different treatment fields like in the area of gastrointestinal surgery and urology. The Company's lead product is RefluxStop, a passive, implant to prevent gastroesophageal reflux disease (GERD).

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

02-19 - Q4 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
09/12/25	52.40 kr	-1.87%	13,573
08/12/25	53.40 kr	+2.10%	13,742
05/12/25	52.30 kr	-0.95%	32,662
04/12/25	52.80 kr	+0.38%	10,813
03/12/25	52.60 kr	-0.94%	10,782

Delayed Quote Nasdaq Stockholm, December 09, 2025 at 04:29 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.881EUR

Average target price

6.664EUR

Spread / Average Target

+36.52%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 16:29:33 09/12/2025 GMT			5-day change	1st Jan Change
52.40 ^SEK	-1.87%		-1.32%	+52.33%

11-25	Implantica AG Announces its Innovative Device, RefluxStop®	CI
10-31	Implantica AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Capitalization	1.38B 1.61B 1.3B 1.21B 2.22B 145B 2.43B 15.13B 5.86B 68.38B 6.03B 5.9B 251B	P/E ratio 2025 *	-18.9x	P/E ratio 2026 *	-13.9x
Enterprise value	1.33B 1.55B 1.25B 1.16B 2.15B 140B 2.34B 14.6B 5.65B 65.99B 5.82B 5.69B 242B	EV / Sales 2025 *	653x	EV / Sales 2026 *	381x
Free-Float	4.86%	Yield 2025 *	-	Yield 2026 *	-

11-25	Implantica AG Announces its Innovative Device, RefluxStop®	CI
10-31	Implantica AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
10-31	Implantica AG, Q3 2025 Earnings Call, Oct 31, 2025
10-31	Corporate earnings calendar for October 31, 2025: Intesa, Spie, and Scor, with Exxon Mobil still to come
10-31	Implantica Increases Revenue and Narrows Operating Loss	FW
10-31	Market Calendar: Friday, October 31	FW
10-30	Friday, October 31: Market and Macroeconomic Calendar	FW
10-27	Earnings calendar for October 27-31: Apple, Microsoft, Amazon, and others report
10-16	Pareto Raises Target Price for Implantica as FDA Approval Nears Turning Point	FW
10-16	Pareto Securities Raises Target Price for Implantica to 73 Kronor (54), Reiterates Buy	FW
10-13	Implantica Completes Key Milestone in US FDA Review for Acid Reflux Device	MT
10-13	Implantica Completes FDA 100-Day Meeting for RefluxStop PMA Application	CI
10-13	Implantica Completes Critical 100-Day Meeting with FDA	FW

10-16	Pareto Raises Target Price for Implantica as FDA Approval Nears Turning Point	FW
10-16	Pareto Securities Raises Target Price for Implantica to 73 Kronor (54), Reiterates Buy	FW
10-13	Implantica Completes Key Milestone in US FDA Review for Acid Reflux Device	MT
10-13	Implantica Completes FDA 100-Day Meeting for RefluxStop PMA Application	CI
10-13	Implantica Completes Critical 100-Day Meeting with FDA	FW

Implantica AG Share Price

Equities

IMP A SDB

SE0014855029

Medical Equipment, Supplies & Distribution

Valuation: Implantica AG

Chart: Implantica AG

Latest news: Implantica AG

Last Transcript: Implantica AG

Analysts' recommendations: Implantica AG

Press Releases: Implantica AG

News in other languages: Implantica AG

Quotes and Performance

Course Extremes

Managers and Directors: Implantica AG

Medical Equipment

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

11-25	RefluxStop® "Best in Class" at Japan Foregut Conference as 5-Year Data and Extensive Safety Cohort is Presented to 120 Leading Surgeons	AQ
11-11	RefluxStop® takes center stage at 2025 European Foregut Society meeting	AQ
10-31	Implantica publishes Interim Report January - September 2025 (Q3)	AQ
10-27	Implantica presents the third quarter 2025 on October 31 at 15:00 CET	AQ
10-13	Implantica completes FDA 100-Day Meeting for RefluxStop® PMA application	AQ

07-01	Les actions en mouvement : Walmart met à mal VusionGroup
06-04	Les actions en mouvement : contrats majeurs et commandes importantes
18/09/24	Actualización de las fuertes variaciones del día: Implantica revoluciona el tratamiento del reflujo, Novo Nordisk se enfrenta a la incertidumbre
18/09/24	Les actions en mouvement : Implantica révolutionne le traitement du reflux, Novo Nordisk face à l'incertitude

1 day	-1.87%
1 week	-1.32%
Current month	-1.50%
1 month	-2.96%
3 months	-13.39%
6 months	+26.11%
Current year	+52.33%

1 week	51.5	53.9
1 month	50	60.6
Current year	22	86.4
1 year	22	86.4
3 years	15.4	86.4
5 years	15.4	178.9
10 years	15.4	178.9

Manager	Title	Age	Since
Peter Forsell CEO	Chief Executive Officer	71	31/12/2014
Andreas Öhrnberg DFI	Director of Finance/CFO	47	31/12/2019
Stephan Siegenthaler PRN	Corporate Officer/Principal	68	-

Director	Title	Age	Since
Liselott Kilaas CHM	Chairman	66	31/12/2019
Johan Bojs BRD	Director/Board Member	61	31/12/2019
Tomas Puusepp BRD	Director/Board Member	70	31/12/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
IMPLANTICA AG	-1.87%	-1.32%	+48.65%	+26.88%	1.61B
SHOCKWAVE MEDICAL	-0.01%	+0.01%	+0.01%	+40.13%	12.57B
PENUMBRA, INC.	-1.53%	+0.75%	+20.34%	+34.07%	11.55B
MASIMO CORPORATION	+0.44%	+0.17%	-15.98%	+2.84%	7.57B
GETINGE AB	-1.39%	-3.21%	+17.88%	-15.11%	6.01B
ASAHI INTECC CO., LTD.	+0.07%	+4.93%	+15.97%	+23.67%	5.2B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	-0.61%	-1.74%	+5.14%	+0.08%	5.06B
APT MEDICAL INC.	-1.53%	-1.54%	-10.24%	+69.42%	4.81B
INARI MEDICAL, INC.	+0.05%	-.--%	+56.56%	+14.26%	4.7B
CHEMOMETEC A/S	-0.68%	-4.64%	+50.25%	-13.01%	1.99B
Average	-0.69%	-0.72%	+18.86%	+18.32%	6.11B
Weighted average by Cap.	-0.59%	-0.38%	+11.88%	+22.44%

	2025 *	2026 *
Net sales	2.04M 2.38M 1.92M 1.78M 3.29M 214M 3.59M 22.37M 8.66M 101M 8.91M 8.72M 370M	3.54M 4.11M 3.32M 3.09M 5.69M 371M 6.21M 38.73M 15M 175M 15.43M 15.1M 641M
Net income	-17.96M -20.87M -16.86M -15.67M -28.89M -1.88B -31.52M -196M -76.09M -888M -78.31M -76.64M -3.25B	-24.45M -28.4M -22.95M -21.34M -39.33M -2.56B -42.91M -267M -104M -1.21B -107M -104M -4.43B
Net Debt	-48.38M -56.21M -45.42M -42.22M -77.82M -5.07B -84.9M -529M -205M -2.39B -211M -206M -8.77B	-33.3M -38.68M -31.26M -29.06M -53.56M -3.49B -58.44M -364M -141M -1.65B -145M -142M -6.03B